Log in

IMCR Immunocore Holdings plc NASDAQ · United Kingdom

Immunocore Holdings (IMCR) news

Top story · Aug 6, 2026 · SEC filing 8-K

Immunocore reports results

On August 6, 2026, Immunocore Holdings plc (the " Company ") issued a press release announcing its financial results for the second quarter ended June 30, 2026, as well as other recent corporate updates.

Source: 8-K filed Aug 6, 2026 on SEC EDGAR

Latest Immunocore Holdings news

We have not published a story on Immunocore Holdings yet. When there is news, it will appear here.

Immunocore Holdings annual financials

LineFY2025FY2024
Research and development$274.9 million$222.2 million
Net income (loss)-$35.5 million-$51.1 million
Cash from operations-$10.7 million$26.1 million
Cash and equivalents$467.7 million$455.7 million
Short-term investments$396.4 million$364.6 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $484.9 million, plus short-term investments of $395.3 million, $880.2 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Immunocore Holdings

What is the ticker symbol of Immunocore Holdings?

Immunocore Holdings plc trades under the ticker IMCR on NASDAQ.

Where is Immunocore Holdings listed?

Immunocore Holdings plc is listed on NASDAQ.

What is the SEC CIK of Immunocore Holdings?

The SEC Central Index Key (CIK) for Immunocore Holdings plc is 1671927. Its filings are on SEC EDGAR.

How many shares does Immunocore Holdings have outstanding?

51,498,617 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.

Which country or territory is Immunocore Holdings listed under?

Our directory records Immunocore Holdings plc under United Kingdom.

What does Immunocore Holdings do?

Our directory classifies Immunocore Holdings plc as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Immunocore Holdings?

The ISIN recorded for Immunocore Holdings plc is US45258D1054.

Does aibio.space cover Immunocore Holdings?

aibio.space lists Immunocore Holdings plc among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Immunocore Holdings incorporated?

SEC records list its state or country of incorporation as X0.

Is Immunocore Holdings profitable?

Immunocore Holdings plc reported a net loss of $35.5 million for the fiscal year ended Dec 31, 2025, and used $10.7 million of cash in operations, per its annual report to the SEC.

How much does Immunocore Holdings spend on research and development?

$274.9 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Immunocore Holdings have?

$880.2 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

What is Immunocore Holdings's market cap?

We do not publish live share prices. In its annual report, Immunocore Holdings plc put the market value of shares held by non-affiliates (public float) at $1.50 billion as of Jun 30, 2025.

Is Immunocore Holdings a smaller reporting company?

SEC records list Immunocore Holdings plc's filer category as: Large accelerated filer.

Where is Immunocore Holdings headquartered?

SEC records list its business address as 90 PARK DRIVE, OXFORDSHIRE, United Kingdom, OX14 4RY.

Investor discussion: Immunocore Holdings

Members talk about Immunocore Holdings (IMCR). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Immunocore Holdings, newest first. Each line links the filing it comes from.

  1. Financings

    Reported a financing. SEC Form 424B7. Source

  2. Distress

    Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:IMCR on TradingView.

SEC filings and registration

SEC name
Immunocore Holdings plc
CIK
1671927
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
IMCR (Nasdaq)
State or country of incorporation
X0
Fiscal year ends
December 31
Filer category
Large accelerated filer
Business address
90 PARK DRIVE, OXFORDSHIRE, United Kingdom, OX14 4RY
Phone
01235 5430281
Shares outstanding
51,498,617 as of 2026-07-31 (10-Q filed 2026-08-06)
Former names
Immunocore Ltd

Recent filings (8-K and 6-K are the company's own announcements)

  • 8-K filed 2026-09-14
  • 10-Q filed 2026-08-06
  • 8-K filed 2026-08-06
  • 8-K filed 2026-05-27
  • 8-K filed 2026-05-06
  • 10-Q filed 2026-05-06
  • DEF 14A filed 2026-04-16
  • 8-K filed 2026-02-25

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Immunocore Holdings plc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IMCR, recorded under United Kingdom. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Immunocore Holdings plc
Ticker
IMCR
Listing
NASDAQ
Country or territory
United Kingdom
Business scope
Biotechnology
ISIN
US45258D1054
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.